Cassava Sciences Long-Term Debt 2011-2026 | SAVA

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Cassava Sciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	139 K	235 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
235 K	139 K	187 K

Quarterly Long-Term Debt Cassava Sciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	35 K	62 K	-	114 K	139 K	164 K	188 K	213 K	235 K	235 K	235 K	235 K	-	23 K	45 K	68 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
235 K	23 K	142 K

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	806 K	$ 4.5	0.45 %	$ 862 M	Canada
ADC Therapeutics SA ADCT	6.99 M	$ 3.83	1.32 %	$ 105 M	Schweiz
Agenus AGEN	30.5 M	$ 3.64	9.31 %	$ 108 M	USA
Agios Pharmaceuticals AGIO	21.8 M	$ 35.08	-0.36 %	$ 2.03 B	USA
Akebia Therapeutics AKBA	48.2 M	$ 1.39	0.36 %	$ 357 M	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Aldeyra Therapeutics ALDX	15 M	$ 1.57	-5.42 %	$ 94.3 M	USA
Aligos Therapeutics ALGS	122 K	$ 8.08	1.38 %	$ 79.9 M	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Alnylam Pharmaceuticals ALNY	1.01 B	$ 331.14	3.85 %	$ 43.4 B	USA
Altimmune ALT	34.3 M	$ 3.4	1.8 %	$ 300 M	USA
ALX Oncology Holdings ALXO	4.53 M	$ 1.99	0.81 %	$ 107 M	USA
Amgen AMGN	50 B	$ 344.03	-1.12 %	$ 185 B	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Amneal Pharmaceuticals AMRX	2.57 B	$ 12.27	-1.68 %	$ 3.85 B	USA
Anika Therapeutics ANIK	26.9 M	$ 14.99	1.28 %	$ 220 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
ANI Pharmaceuticals ANIP	309 M	$ 73.8	-0.55 %	$ 1.43 B	USA
Annexon ANNX	23.3 M	$ 5.56	1.0 %	$ 862 M	USA
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
Aptorum Group Limited APM	130 K	$ 0.88	-5.16 %	$ 4.8 M	China
Applied Molecular Transport AMTI	49 K	-	-	$ 10.1 M	USA
Aquestive Therapeutics AQST	45 M	$ 4.12	-0.24 %	$ 441 M	USA
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	2.29 M	-	1.93 %	$ 17.4 M	USA
Arcturus Therapeutics Holdings ARCT	20.8 M	$ 8.14	1.31 %	$ 223 M	Israel
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Ardelyx ARDX	203 M	$ 5.99	0.84 %	$ 1.44 B	USA
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Arcutis Biotherapeutics ARQT	108 M	$ 24.06	1.82 %	$ 3.06 B	USA
Arvinas ARVN	400 K	$ 10.87	0.14 %	$ 771 M	USA
Arrowhead Pharmaceuticals ARWR	104 M	$ 60.28	-1.23 %	$ 8.06 B	USA
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Assembly Biosciences ASMB	2.06 M	$ 29.51	1.72 %	$ 331 M	USA
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA
Alterity Therapeutics Limited ATHE	59.9 K	$ 3.62	1.82 %	$ 8.71 B	Australia